Calliditas Therapeutics AB
Calliditas Therapeutics – developing global, high-value products for patients with significant unmet medical needs.
IgA nephropathy (IgAN), is a slow progressing, chronic disease that over time leads to kidney function deterioration. There are no approved treatments for IgAN and many of these patients go on to develop end-stage renal disease requiring dialysis or kidney transplantation. Calliditas' lead pipeline candidate is an oral, targeted release formulation of budesonide, which is currently in phase III clinical development for the treatment of IgAN.